• People with diabetes in Switzerland now have the opportunity to use the Accu-Chek Insight insulin pump with the automated insulin delivery (AID) system from Diabeloop.
• The Accu-Chek Insight insulin pump from Roche is the first pump with a pre-filled cartridge that can be operated in loop mode.
• The pairing of the Accu-Chek Insight insulin pump, which has been a companion for people with diabetes since 2014, with the self-learning algorithm DBLG1, aims to automate and personalise diabetes management for better therapy outcomes and true relief.
  
  

Basel, 3 May 2021 - Roche today announced that the Accu-Chek Insight insulin pump can now be used with the automated insulin delivery (AID) system from the French MedTech company Diabeloop in Switzerland. People with type 1 diabetes now have the opportunity to use an insulin pump that features a pre-filled insulin cartridge and a spectrum of infusion sets to suit individual needs in a CE-labelled hybrid-closed loop system. The new set-up is a first result of the recently established partnership between Roche and Diabeloop allowing for convenience and personalisation in insulin pump therapy while contributing to more effective diabetes management and improving therapy outcomes.

Using artificial intelligence, the hybrid closed-loop system from Diabeloop mimics pancreatic functions and enables automated blood glucose control. Its core element is a unique self-learning algorithm, DBLG1, hosted on a dedicated handset and now connected via Bluetooth technology to the Accu-Chek Insight insulin pump and a continuous glucose monitor (CGM). Every five minutes, the DBLG1 algorithm analyses the patient’s glucose levels and automatically calculates the needed dose of insulin in real time, taking into account the individual physiology, history and data inputs for meals and physical activity.

“The Accu-Chek Insight insulin pump is designed for easy and convenient insulin pump therapy. Its users appreciate the sleek and intuitive design, the possibility to set a very low basal rate and above all the pre-filled cartridge for more comfort,” said Marcel Gmuender, Global Head of Roche Diabetes Care. “With the ability to connect our well-established Accu-Chek Insight insulin pump with a hybrid closed-loop system, we are taking a great step towards the personalised treatment of diabetes in Switzerland.” Study data demonstrate a significant improvement in glycaemic control, a reduction in hypoglycaemic risk in adults with type 1 diabetes, and more time in range using the AID algorithm from Diabeloop^1,2 which is seen to be positively associated with long-term health³. “For people with diabetes, the hybrid closed-loop system helps to simplify everyday treatment by reducing the constant burden associated with dozens of calculations and therapeutic decisions to be taken in order to control the blood glucose levels day and night,” concluded Marcel Gmuender.

The launch of the innovative diabetes management solution in first countries across Europe and now in Switzerland marks Roche’s first step in the field of automated insulin delivery (AID) and is a milestone in its strategy of integrated Personalised Diabetes Management (iPDM).

About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.

Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.

Since 2017, mySugr, one of the most popular diabetes management apps, is part of Roche Diabetes Care.

For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Benhamou PY, Franc S, Reznik Y, et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digital Health. 2019;1: e17–25
[2] Amadou C, Franc S, Benhamou PY, Lablanche S, Huneker E, Charpentier G, Penfornis A; Diabeloop Consortium. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up. Diabetes Care. 2021 Jan 11:dc201809.
[3] Beck at al. 2018: Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, Close KL. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019 Mar;42(3):400-405.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Attachment

• 03052021_MR_Diabeloop